Search for a trial

1 results

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial to
Evaluate the Safety and Efficacy of AMX0035 Versus Placebo for 48-week Treatment of
Adult Patients with Amyotrophic Lateral Sclerosis (ALS)

Approved WMORecruiting

This study has been transitioned to CTIS with ID 2023-508511-23-00 check the CTIS register for the current data. To assess safety and efficacy of AMX0035 for treatment of ALS.

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial to Evaluate the Safety and Efficacy of AMX0035 Versus Placebo for 48-week Treatment of Adult Patients with Amyotrophic Lateral Sclerosis (ALS)

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial to
Evaluate the Safety and Efficacy of AMX0035 Versus Placebo for 48-week Treatment of
Adult Patients with Amyotrophic Lateral Sclerosis (ALS)